Skip to main content
. 2016 Jul 14;7(7):e180. doi: 10.1038/ctg.2016.38

Table 1. Baseline characteristics of study population.

  Exercise group (n=13) Control group (n=12) P-value
Gender, n (male/female) 9/4 10/2 0.635
Age, years 53 (48–55) 51 (38–57) 0.478
Weight, kg 79.5 (59–82) 71.2 (62–80) 0.918
Height, cm 163 (152–175) 166 (155–169) 0.809
BMI (kg/m2) 27.5 (22.4–28.9) 27.4 (25.3–30) 0.705
HR (bpm) 59±6.2 60±6.5 0.527
MAP (mm Hg) 81.1±11.2 79.3±5.7 0.609
       
Etiology of cirrhosis, n     0.852
 HCV 5 3 1.000
 NASH 3 4  
 Alcohol 1 2  
 Other 4 3  
       
Presence of HE (yes/no) 3/8 3/8  
Presence of ascites (yes/no) 0/11 2/11 0.476
History of variceal bleeding (yes/no) 4/7 3/8 1.000
Presence of small varices (yes/no) 8/5 9/3 0.673
Use of NSBB, % 100 100  
CTP score 6 (5–7) 6 (5–7) 0.401
MELD score 9 (8–12) 12 (7–14) 0.606
HVPG, mm Hg 14.5 (12.3–18) 11.5 (3.5–17.5) 0.235
Platelets, K/μl 86 (64–130) 67 (54–94) 0.332
Glucose, mg/dl 100 (78–122) 88 (81–107) 0.847
Creatinine, mg/dl 0.8 (0.7–0.9) 0.7 (0.6–0.8) 0.217
Sodium, mmol/l 139 (137–140) 139 (137–140) 0.847
Potassium, mmol/l 4.3 (4.1–4.6) 4.4 (4–4.6) 0.847
Carbon dioxide, mmol/l 25 (24–25.5) 24 (23–25.3) 0.217
Total bilirubin, mg/dl 1.4 (0.7–2.3) 2.0 (1.3–2.8) 0.133
ALT, U/l 42 (32–77) 40 (32–67) 0.519
AST, U/l 68 (38–97) 56 (40–78) 0.606
Albumin, g/dl 3.6 (3.2–3.9) 3.7 (2.8–3.7) 0.797
INR 1.2 (1.1–1.3) 1.3 (1.2–1.3) 0.438

ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; CTP, Child-Turcotte-Pugh score; HCV, hepatitis C virus; HE, hepatic encephalopathy; HR, heart rate; HVPG, hepatic venous pressure gradient; INR, international normalized ratio; MAP, mean arterial pressure; MELD, model for end-stage liver disease; NASH, Non-alcoholic steatohepatitis; NSBB, non-selective beta-blockers.

Results are expressed as mean (s.d.), median (IQR) or relative frequencies. Statistical test Mann–Whitney U-test or χ2 or Fisher’s test as appropriate.